BRAF inhibitor dabrafenib and MEK inhibitor trametinib

DRUG2 trials

Sponsors

UNC Lineberger Comprehensive Cancer Center, Fujian Medical University

Conditions

BRAF Mutant MelanomaStage III MelanomaStage IV MelanomaThyroid CancerThyroid NeoplasmsUnresectable Melanoma

Phase 2

LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations

CompletedNCT01726738

UNC Lineberger Comprehensive Cancer CenterBRAF Mutant Melanoma, Stage III Melanoma, Stage IV Melanoma +1

Start: 2013-04-04End: 2020-09-17Updated: 2020-11-23

Unknown Phase

Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer

RecruitingNCT07419932

Fujian Medical UniversityThyroid Cancer, Thyroid Neoplasms

Start: 2025-12-23End: 2029-06-30Target: 120Updated: 2026-02-19

Related Papers

Abstract 2051: Baseline and adaptive activated kinome profiling identifies PTK6 as a mediator of resistance to vemurafenib and dabrafenib but not encorafenib in <i>BRAFV600</i>-mutant metastatic melanoma

Cancer Research2025-04-21